Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: The impact of previous intravesical treatment

International Journal of Urology

Volumn 15, Issue 11, 2008, Pages 976-980

  Okamura, Takehiko ^a   Akita, Hidetoshi ^a   Imura, Makoto ^b   Kaneko, Tomoyoshi ^c   Mizuno, Kentaro ^d   Tozawa, Keiichi ^d   Kohri, Kenjiro ^d  

^a ANJO KOSEI HOSPITAL   (Japan)

^b JA Aichi Kamo Hospital   (Japan)

^c Meijo Hospital   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Bacillus Calmette Gu rin; Intravesical instillation; Previous treatment episode; Superficial bladder cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETREATMENT; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 54849418638     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02146.x     Document Type: Article

References (27)

1. Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J. Urol. 1989 142 : 719 22.
2. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J. Urol. 1992 148 : 797 801.
3. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder cancer: a randomized Southwest Oncology Group Study. J. Urol. 2000 163 : 1124 9.
4. Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J. Long-term follow-up of patients with stage T1 high grade transitional cell carcinoma managed by bacillus Calmette-Guérin immunotherapy. Urology. 2007 69 : 78 82.
5. Gårdmark T, Jahnson S, Wahlquist R, Wijkström H, Malmström PU. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int. 2007 99 : 817 20.
6. Rawls WH, Lamm DL, Lowe BA et al. Fatal sepsis following intravesical bacillus Calmette-Guérin administration for bladder cancer. J. Urol. 1990 144 : 1328 30.
7. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J. Urol. 2006 175 : 2004 10.
8. Hinotsu S, Akaza H, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999 86 : 1818 26.
9. Günlüsoy B, Deǧimenci T, Arslan M, Nergiz N, Minareci S, Ayder AR. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Urol. Int. 2005 75 : 107 13.
10. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007 100 : 33 6.
11. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guérin for high risk Ta, T1 bladder cancer. J. Urol. 2007 177 : 1727 31.
12. Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K, Kohri K. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guérin instillation for preventing the recurrence of initially resistant superficial bladder cancers. J. Urol. 1996 156 : 967 71.
13. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J. Urol. 2006 175 : 1634 40.
14. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002 168 : 1964 70.
15. Martínez-Pineiro JA, Martínez-Pineiro L, Solsona E et al. Has a 3-fold decreased dose of Bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J. Urol. 2005 174 : 1242 7.
16. Okamura T, Akita H, Tozawa K, Kawai N, Nagata D, Bacillus Kohri K. Calmette-guérin refractory superficial bladder cancers: focus on pretreatment episodes. Int. J. Clin. Oncol. 2003 8 : 168 73.
17. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J. Urol. 2003 170 : 964 9.
18. Chen F, Zhang G, Iwamoto Y, See WA. Bacillus Calmette-Guérin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking α5β1 integrin. J. Urol. 2003 170 : 605 10.
19. Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guérin for superficial bladder tumors. Urol. Int. 2005 75 : 114 18.
20. Naoe M, Ogawa Y, Takeshita K et al. Bacillus Calmette-Guérin- pulsed dendritic cells stimulate natural killer cells and γδT cells. Int. J. Urol. 2007 14 : 532 8.
21. Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int. J. Urol. 2007 14 : 140 6.
22. Martínez-Piñeiro JA, Flores N, Isorna S et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002 89 : 671 80.
23. Andius P, Holmäng S. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int. 2004 93 : 980 4.
24. Yang TB, Zeng FH, Sun ZQ. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study. Chin. Med. J. 2006 119 : 1821 8.
25. McHugh LA, Griffiths TR. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int. 2004 93 : 60 3.
26. Soloway MS, Lee CT, Steinberg GD, Ghandi AA, Jewett MA. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Urol. Oncol. 2007 25 : 338 40.
27. Raj GV, Herr H, Serio AM et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J. Urol. 2007 177 : 1283 6.